Erdafitinib | C25H30N6O2 - PubChem
Erdafitinib | C25H30N6O2 | CID 67462786 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ...
Erdafitinib - National Cancer Institute
Erdafitinib is also being studied in the treatment of other types of cancer. More About Erdafitinib. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Research Results and Related Resources. Targeted Cancer Therapies. Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer . Clinical …
Erdafitinib - Wikipedia
Erdafitinib Uses, Side Effects & Warnings - Drugs.com
Homepage | BALVERSA® (erdafitinib)
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer
Videos Of Erdafitinib
Balversa (erdafitinib) dosing, indications, interactions, adverse effects, a…
Erdafitinib: A Novel Therapy For FGFR-mutated Urothelial …
Erdafitinib Uses, Side Effects & Warnings - Drugs.com
Erdafitinib - An Overview | ScienceDirect Topics
Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discoveredthe drug an…
Images Of Erdafitinib
WHAT IS BALVERSA ® (erdafitinib)? BALVERSA ® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery: which has a certain type of abnormal fibroblast growth factor receptor (FGFR) gene, and; who have tried at least one other chemotherapy medicine that contains platinum, and it did not …
Explore
Summary: Erdafitinib (Balversa, Janssen Pharmaceuticals) is a novel pan-FGFR inhibitor recently approved for the treatment of patients with advanced urothelial cancer with specific FGFR genetic alterations who have received at least one prior platinum-containing regimen. Erdafitinib binding to the FGFR2 and FGFR3 receptors inhibits FGF activity, resulting in cell death. …
Erdafitinib: Uses, Interactions, Mechanism Of Action - …
242 rows · Erdafitinib is a quinoxaline derivative (Fig. 8 A) [65] that was approved for the first-line treatment of urothelial bladder cancer bearing susceptible FGFR2/3 mutations or for the second-line treatment of locally advanced or metastatic bladder cancer following platinum-based chemotherapy (Table 8) [47]. Importantly, urothelial cancers are the fourth most prevalent …
Erdafitinib Uses, Side Effects & Warnings - Drugs.com
665 rows · Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation 4,5.
Balversa (erdafitinib) Dosing, Indications, Interactions, …
04/05/2021 · Erdafitinib is used to treat bladder cancer that has spread to other parts of the body (metastatic), or cannot be removed with surgery. Erdafitinib is used only if your cancer has a specific genetic marker (an abnormal "FGFR" gene). Your doctor will test you for this gene. Erdafitinib is usually given after other treatments have failed.